DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast- 2034′′ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover Key Insights into the Metastatic Prostate Cancer Market with DelveInsight’s In-Depth Report @ Metastatic Prostate Cancer Market Size

Key Takeaways from the Metastatic Prostate Cancer Market Report

• On January 07, 2026- Novartis Pharmaceuticals initiated a Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
• On January 05, 2026, Merck Sharp & Dohme LLC announced a phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02).
• As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., 2024–2034.
• The United States had the highest number of diagnosed prostate cancer cases in 2023, with approximately 1,506,000 reported cases.
• In 2023, total cases of metastatic CSPC/HSPC and metastatic CRPC were around 108,000 and 132,000, respectively, in the 7MM. These cases are expected to increase by 2034.
• In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in locally advanced (Stage I–III), accounting for over 903,700 cases, followed by biochemical recurrence/progressive and metastatic cases, respectively, in 2023.
• Among the EU4, Germany accounted for the highest number of prevalent metastatic prostate cancer cases, followed by France, whereas Spain accounted for the lowest number of cases in 2023.
• The total number of diagnosed prevalent cases of prostate cancer in Japan was ~282,100 in 2023 and is expected to increase during the forecast period.
• The leading Metastatic Prostate Cancer Companies such as AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others.
• Promising Metastatic Prostate Cancer Therapies such as Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A and others.

Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Metastatic Prostate Cancer Market Forecast @ Metastatic Prostate Cancer Market Drivers and Barriers

Metastatic Prostate Cancer Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Prostate Cancer
• Total Diagnosed Prevalent Cases of Prostate Cancer
• Age-specific Cases of Prostate cancer
• Total Diagnosed Cases of Prostate Cancer by Clinical Stages
• Total Metastatic Cases of Prostate Cancer
• Total Treated Cases of mCRPC
• Total Treated Cases of mCSPC/mHSPC

Download the Report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Prevalence

Metastatic Prostate Cancer Marketed Drugs

• NUBEQA (darolutamide): Bayer

NUBEQA (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, inhibiting the receptor function and the growth of prostate cancer cells. NUBEQA is indicated for treating adult patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer in combination with docetaxel.

• ERLEADA (apalutamide): Janssen

ERLEADA is a next-generation oral androgen receptor inhibitor that blocks the androgen-signaling pathway in prostate cancer cells. ERLEADA inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the androgen receptor, by stopping the androgen receptor from entering the cancer cells, and by preventing the AR from binding to the DNA of the cancer cell. It is indicated for treating patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.

Metastatic Prostate Cancer Emerging Drugs

• MGC018 (vobramitamab duocarmazine): MacroGenics

MGC018 (vobramitamab duocarmazine) is an investigational ADC comprised of a humanized B7-H3 mAb conjugated via a cleavable linker to the prodrug Seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA). MacroGenics began enrolling the TAMARACK Phase II study of vobramitamab duocarmazine (vobra duo) in patients with mCRPC under an amended protocol during the second quarter. This study is designed to evaluate vobra duo at two different doses, 2.0 mg/kg or 2.7 mg/kg every 4 weeks, across 100 patients. MacroGenics is also evaluating the activity of MGC018 plus lorigerlimab (an investigational PD-1 × CTLA-4 bispecific DART® molecule) in a Phase 1 study in patients with advanced solid tumors.

• Bavdegalutamide (ARV-110): Arvinas

ARV-110 is an oral PROTAC protein degrader that targets the androgen receptor for potentially treating men with mCRPC and who have progressed on existing therapies. ARV-110 has demonstrated activity in preclinical models of androgen receptor mutation or overexpression, both common mechanisms of resistance to currently available androgen receptor-targeted therapies. The company plans to initiate a global Phase III trial with a confirmed bavdegalutamide dose in metastatic castration-resistant prostate cancer (mCRPC) for patients with AR T878/H875 tumor mutations by the First half of 2024.

Get In-Depth Knowledge on Metastatic Prostate Cancer Market Trends and Forecasts with DelveInsight @ Metastatic Prostate Cancer Treatment Market

Metastatic Prostate Cancer Drugs Market Insights

Currently, the Metastatic Prostate Cancer market holds a diverse range of therapeutic alternatives for treatment, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, radioligand therapies, GnRH receptor antagonists, and others in different lines of treatment. Androgen receptor pathway inhibitors are a mainstay of treatment for patients with metastatic castration-resistant prostate cancer. There are currently four approved androgen receptor pathway inhibitors in the United States: three anti-androgens — apalutamide, enzalutamide, and darolutamide, as well as an androgen receptor pathway inhibitor, abiraterone acetate. In men with mCRPC and select HRR pathway alterations, PARPi treatment has been shown to induce objective tumor responses and improve progression-free and overall survival. The FDA has approved four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) for men with metastatic castration-resistant prostate cancer.

Metastatic Prostate Cancer Therapies and Companies

• Curium US LLC: Abiraterone with Prednisone or Enzalutamide
• Carolina Research Professionals LLC: Enzalutamide
• Merck Sharp & Dohme LLC: Docetaxel/Ifinatamab Deruxtecan/MK-5684
• Sanofi: Aflibercept/Docetaxel
• Janssen Research & Development LLC: Abiraterone acetate
• Halda Therapeutics OpCo Inc.: HLD-0915

Scope of the Metastatic Prostate Cancer Market Report

• Study Period: 2020-2034

• Coverage: 7MM

• Metastatic Prostate Cancer Companies- AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others.

• Metastatic Prostate Cancer Therapies- Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A, and others.

• Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and emerging therapies

• Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

Explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Metastatic Prostate Cancer Market Forecast @ Metastatic Prostate Cancer Clinical Trials Assessment

Table of Contents

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Disease Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis

14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17. Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market